News Headlines

31. Lilly To Acquire Orna Therapeutics To Advance Cell Therapies 2/9/2026

    Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.

32. Fresenius Kabi And Phlow Corp. Announce First-Ever, End-To-End, U.S. Manufacturing Collaboration For Epinephrine Injection, USP 2/9/2026

    Fresenius Kabi and Phlow Corp. announced today a first-of-its-kind collaboration to onshore the manufacture of Epinephrine Injection, USP, an essential medicine long at risk of chronic shortage in the U.S. and widely used in hospitals nationwide.

33. Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology 2/8/2026

    Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, today announced a strategic collaboration with Eli Lilly and Company ("Lilly") to advance novel medicines in oncology and immunology.

34. Eisai And Henlius Enter Into Exclusive Commercial License Agreement For Anti-PD-1 Antibody Serplulimab In Japan 2/5/2026

    Eisai Co., Ltd. ("Eisai") and Shanghai Henlius Biotech, Inc. ("Henlius") today announced the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name; marketed as Hetronifly® in the EU) in Japan.

35. AGC Biologics Seattle Site Now Certified To Manufacture Biologics For Largest Pharmaceutical Market In South America 2/5/2026

    AGC Biologics’ Seattle site earned Anvisa GMP certification, enabling biologics and biosimilars produced there to enter Brazil’s expanding pharmaceutical market and strengthening the facility’s global regulatory track record.

36. Eurofins CDMO Alphora Joins International Consortium Project To Advance Next Generation ADC Expression Platform 2/5/2026

    As part of this initiative, Eurofins CDMO Alphora (Canada) is collaborating with Daresbury Proteins Ltd. (UK) to contribute its development and manufacturing expertise to the NextGen ADC Platform: Engineering High Yielding Expression Vectors and Peptide Linker Tags for Advanced ADC Production initiative.

37. OXB Signs New Multi-Year Commercial Supply Agreement With Bristol Myers Squibb 2/4/2026

    OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic partnership with Bristol Myers Squibb (“BMS”) (NYSE: BMY), signing a new Commercial Supply Agreement (CSA) for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.

38. Evogene And Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement For BMC128, A Microbiome-Based Therapeutic For Renal And Lung Cancer 2/4/2026

    Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biopharmaceuticals Co., Ltd. ("Lishan Biotech"), a China-based clinical-stage biotechnology company focused on innovative therapies in the fields of immunity and inflammation, today announced that Biomica Ltd. ("Biomica"), Evogene's subsidiary and Lishan Biotech entered into an exclusive worldwide licensing agreement for BMC128 (designated as LS-LBP-002 by Lishan Biotech), a first-in-class microbiome-based therapeutic designed to enhance anti-tumor immune activity.

39. Saya Biologics And Kashiv BioSciences Partner To Bring A Biosimilar Supportive Oncology Therapy To Mexico And CAC 2/4/2026

    Saya Biologics (Saya Bio), a Mexican biopharmaceutical company committed to expanding access to high-quality and affordable biologic treatments, and Kashiv BioSciences, a vertically integrated global biopharmaceutical company specializing in the research, development, and manufacturing of biologic medicines, have announced a strategic collaboration to register and commercialize a supportive oncology therapy in Mexico and the Central America & Caribbean (CAC) region.

40. BioSelective Capital Investments Completes Acquisition Of BioDuro's Irvine, California Drug Product Development And Manufacturing Operations 2/4/2026

    BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets.